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Background
Cancer remains a major health concern in the manage-
ment of HIV infection in areas of the world with and
without access to highly active antiretroviral therapy. In
the USA alone, approximately 56,000 people were newly
diagnosed with HIV infection in 2006; 53% of these new
diagnosis occurred in gay and bisexual men but Black/
African American men (45%) ,women (27%) , and His-
panics (17%) were also strongly affected [1]. Recruitment
of members of these groups into cancer clinical trials
has traditionally been challenging [2]. Among domestic
AMC studies, a relatively small percentage of all partici-
pants have included women (8%), African-Americans
(29%), and Hispanics (21%). Patient Navigation has been
identified as an effective strategy to reduce barriers to
care as well as to increase access to cancer clinical trials
[3]. In an effort to bolster opportunities for HIV-
infected minorities, women, and medically underserved
populations to become involved in AMC clinical trials, a
PN initiative was implemented in seven AMC sites
located in Boston, Los Angeles, San Diego, Houston,
Columbus, and Honolulu. The main objectives of the
PN initiative were to provide greater opportunity for
minority groups and women to participate in AMC-
sponsored cancer trials and to increase awareness of
HIV/AIDS malignancies in the local communities where
the PNs worked. From January 2010 to April 2011, PNs
implemented multi-strategy activities to increase the
enrollment of women and minorities in AMC trials.
PNs reported 466 activities in the programmatic areas
of recruitment and retention, community outreach and
education and awareness. Recruitment and retention
refers activities to recruit new participants and increase
retention in AMC trials. Community outreach was tar-
geted to the medical community or the general population
to increase their awareness of AIDS-related malignancies.
Education and awareness were activities to educate the
community on HIV-related malignancies in general and
AMC-sponsored clinical trials in specific. PNs efforts were
concentrated on community outreach (54%, n=251), fol-
lowed by recruitment and retention (28%, n=129) and
education and awareness 18% (n=86).
Conclusion
AMC-PNs conducted activities that raised awareness in
their local communities of AIDS-related malignancies,
developed partnerships with local health community orga-
nizations and identified areas where further communica-
tion was needed. PNs took the lead in developing a PN
brochure and in the design of several tailored recruitment
strategies. The PN program is making important inroads
into behavioral interventions to increase participation of
minorities and underserved populations in AMC trials.
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